Bausch Health Companies Stock Performance
| BHC Stock | USD 7.46 0.01 0.13% |
The firm shows a Beta (market volatility) of 0.34, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bausch Health's returns are expected to increase less than the market. However, during the bear market, the loss of holding Bausch Health is expected to be smaller as well. At this point, Bausch Health Companies has a negative expected return of -0.33%. Please make sure to confirm Bausch Health's accumulation distribution, day typical price, and the relationship between the skewness and rate of daily change , to decide if Bausch Health Companies performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Bausch Health Companies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical indicators remain rather sound which may send shares a bit higher in March 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (0.13) | Five Day Return (4.73) | Year To Date Return (6.05) | Ten Year Return (95.39) | All Time Return 1.4 K |
Last Split Factor 2:1 | Ex Dividend Date 2010-11-10 | Last Split Date 2000-10-16 |
1 | Why Bausch Health is a Top Momentum Stock for the Long-Term | 11/04/2024 |
2 | Institutional Stake in Bausch Health Companies Inc. | 11/29/2024 |
3 | Bausch Health names Jonathan Sadeh as chief medical officer | 12/02/2024 |
4 | 116,591 Shares in Bausch Health Companies Inc. Acquired by Centiva Capital LP - MarketBeat | 12/06/2024 |
5 | Carl Icahns Strategic Acquisition of CVR Partners LP Shares | 12/18/2024 |
6 | Bausch Health Companies Inc.s Path To Profitability | 12/26/2024 |
7 | Acquisition by Brett Icahn of 4109 shares of Bausch Health at 8.06 subject to Rule 16b-3 | 12/31/2024 |
8 | Carl Icahns Strategic Acquisition of Icahn Enterprises LP Shares | 01/08/2025 |
9 | Wall Street Analysts See a 25.5 percent Upside in Bausch Can the Stock Really Move This High | 01/16/2025 |
10 | Acquisition by John Paulson of 7716 shares of Bausch Health at 8.1 subject to Rule 16b-3 | 01/17/2025 |
11 | Disposition of 765 shares by Seana Carson of Bausch Health at 9.16 subject to Rule 16b-3 | 01/28/2025 |
12 | Bausch Health Q4 Results to Focus on 2025 Outlook, Potential Full Separation of Bausch Lomb, RBC Says - Marketscreener.com | 01/30/2025 |
| Begin Period Cash Flow | 591 M |
Bausch |
Bausch Health Relative Risk vs. Return Landscape
If you would invest 926.00 in Bausch Health Companies on November 2, 2024 and sell it today you would lose (180.00) from holding Bausch Health Companies or give up 19.44% of portfolio value over 90 days. Bausch Health Companies is generating negative expected returns assuming volatility of 2.5034% on return distribution over 90 days investment horizon. In other words, 22% of stocks are less volatile than Bausch, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Bausch Health Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bausch Health's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bausch Health Companies, and traders can use it to determine the average amount a Bausch Health's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1335
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BHC |
Estimated Market Risk
| 2.5 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.33 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bausch Health is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bausch Health by adding Bausch Health to a well-diversified portfolio.
Bausch Health Fundamentals Growth
Bausch Stock prices reflect investors' perceptions of the future prospects and financial health of Bausch Health, and Bausch Health fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bausch Stock performance.
| Return On Equity | -23.05 | ||||
| Return On Asset | 0.0415 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 23.54 B | ||||
| Shares Outstanding | 367.8 M | ||||
| Price To Earning | 9.26 X | ||||
| Price To Book | 18.78 X | ||||
| Price To Sales | 0.29 X | ||||
| Revenue | 8.76 B | ||||
| Gross Profit | 6.71 B | ||||
| EBITDA | 2.24 B | ||||
| Net Income | (611 M) | ||||
| Cash And Equivalents | 564 M | ||||
| Cash Per Share | 1.34 X | ||||
| Total Debt | 22.39 B | ||||
| Current Ratio | 1.05 X | ||||
| Book Value Per Share | (3.19) X | ||||
| Cash Flow From Operations | 1.03 B | ||||
| Earnings Per Share | (0.48) X | ||||
| Market Capitalization | 2.75 B | ||||
| Total Asset | 27.35 B | ||||
| Retained Earnings | (9.78 B) | ||||
| Working Capital | 1.29 B | ||||
| Current Asset | 984.02 M | ||||
| Current Liabilities | 730.59 M | ||||
About Bausch Health Performance
By analyzing Bausch Health's fundamental ratios, stakeholders can gain valuable insights into Bausch Health's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bausch Health has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bausch Health has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 198.20 | 128.82 | |
| Return On Tangible Assets | (0.07) | (0.07) | |
| Return On Capital Employed | 0.05 | 0.05 | |
| Return On Assets | (0.02) | (0.02) | |
| Return On Equity | 0.52 | 0.55 |
Things to note about Bausch Health Companies performance evaluation
Checking the ongoing alerts about Bausch Health for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bausch Health Companies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bausch Health generated a negative expected return over the last 90 days | |
| The company reported the last year's revenue of 8.76 B. Reported Net Loss for the year was (611 M) with profit before taxes, overhead, and interest of 6.71 B. | |
| Bausch Health has a strong financial position based on the latest SEC filings | |
| About 74.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Bausch Health Q4 Results to Focus on 2025 Outlook, Potential Full Separation of Bausch Lomb, RBC Says - Marketscreener.com |
- Analyzing Bausch Health's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bausch Health's stock is overvalued or undervalued compared to its peers.
- Examining Bausch Health's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bausch Health's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bausch Health's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bausch Health's stock. These opinions can provide insight into Bausch Health's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bausch Stock analysis
When running Bausch Health's price analysis, check to measure Bausch Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bausch Health is operating at the current time. Most of Bausch Health's value examination focuses on studying past and present price action to predict the probability of Bausch Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bausch Health's price. Additionally, you may evaluate how the addition of Bausch Health to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stocks Directory Find actively traded stocks across global markets |